ACS Medicinal Chemistry Letters,
Journal Year:
2024,
Volume and Issue:
15(12), P. 2080 - 2082
Published: Nov. 11, 2024
Psychedelic
compounds,
particularly
psilocybin
and
psilocin,
have
shown
significant
therapeutic
potential
in
treating
neurological
psychiatric
disorders.
However,
their
bioavailability,
rapid
metabolism,
stability
challenges
limited
clinical
use.
This
Patent
Highlight
reviews
recent
innovations
psychedelic
drug
delivery
systems
the
development
of
psilocin
analogs
aimed
at
improving
pharmacokinetic
pharmacodynamic
profiles.
Three
patents─focused
on
controlled-release
systems,
ester
analogs,
acetal/ketal
derivatives─present
novel
approaches
to
enhancing
stability,
efficacy
related
compounds.
These
advancements
promise
more
effective
treatments
for
conditions
such
as
depression,
chronic
pain,
neurodegenerative
diseases.
Journal of Personalized Medicine,
Journal Year:
2024,
Volume and Issue:
14(8), P. 828 - 828
Published: Aug. 4, 2024
Residual
symptoms
are
prevalent
in
major
depressive
disorder
(MDD),
encompassing
a
wide
spectrum
of
such
as
sleep
disturbances,
changes
weight
and
appetite,
cognitive
impairment,
anxiety.
These
consistently
impair
daily
functioning,
diminish
quality
life,
forecast
disease
relapse.
Despite
their
clinical
significance,
residual
lack
unified
definition,
potentially
leading
to
confusion
with
treatment-emergent
ambiguity
across
studies,
thereby
hindering
the
generalizability
research
findings.
While
some
identifies
insomnia
mood
disturbances
critical
indicators,
other
studies
emphasize
different
or
find
no
significant
correlation.
Inconsistencies
defining
symptoms,
well
methodological
differences
contribute
these
conflicting
results.
clinicians
focus
on
alleviating
negative
improve
functional
status,
patients
often
prioritize
achieving
positive
affect
overall
well-being
essential
components
successful
treatment.
It
necessitates
comprehensive
approach
patient
care
depression.
This
review
explores
phenomenon
MDD,
focusing
definitions,
characteristics,
impact
long-term
outcomes.
The
standardized
regulatory
academic
definition
for
leads
varied
interpretations
among
clinicians,
underscoring
need
terminology
guide
effective
treatment
strategies
future
research.
Journal of Drug Issues,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 22, 2024
Our
aim
is
to
understand
how
those
who
use
peyote
in
a
naturalistic
setting
discuss
it
changed
their
lives
and
what
they
attribute
this
change.
To
do
this,
we
draw
on
data
from
photo-ethnography
of
people
attended
ceremonies
rural
Northcentral
Alabama.
Broadly,
found
that
participants
discussed
four
core
areas
change:
reduced
drug
alcohol
misuse,
new
perspectives
life,
improved
mental
health,
physical
health.
The
duration
the
experienced
change
varied
for
each
type
Participants
attributed
ability
endure
challenges,
rewiring
brain,
connecting
with
spiritual
selves.
Findings
give
insights
into
experience
make
sense
peyote.
In
addition,
findings
suggest
specific
research
interested
clinical
therapeutic
settings
relating
particular,
psychedelics
general.
ACS Medicinal Chemistry Letters,
Journal Year:
2024,
Volume and Issue:
16(1), P. 26 - 28
Published: Dec. 18, 2024
Recent
advancements
in
pharmaceutical
research
have
focused
on
developing
novel
psychoactive
compounds
and
receptor
modulators
that
enhance
therapeutic
outcomes
while
minimizing
adverse
effects.
This
Patent
Highlight
examines
three
innovative
approaches:
(1)
transmucosal
delivery
of
dephosphorylated
alkaloids,
(2)
nonhallucinogenic
serotonin
modulators,
(3)
ergoline
analogues
designed
for
treating
neurological
disorders.
These
innovations
offer
breakthroughs
drug
delivery,
targeting,
structural
modifications,
aiming
to
address
challenges
the
treatment
mood
disorders,
diseases,
chronic
pain
improving
bioavailability
reducing
side
effects
hallucinogenic
properties.
ACS Medicinal Chemistry Letters,
Journal Year:
2024,
Volume and Issue:
15(11), P. 1812 - 1814
Published: Oct. 15, 2024
Recent
advancements
in
the
therapeutic
use
of
psychedelic
compounds,
particularly
5-MeO-DMT
and
DMT,
have
demonstrated
significant
potential
treating
various
mental
health
disorders.
This
Patent
Highlight
evaluates
findings
from
multiple
recent
patents
that
explore
novel
applications
these
including
their
severe
psychiatric
conditions
such
as
depression,
anxiety,
trauma-related
The
reveal
innovative
strategies,
combining
with
mood
preparation
agents
to
enhance
safety
efficacy,
developing
DMT
prodrugs
for
improved
pharmacokinetics,
targeting
specific
populations
like
breastfeeding
mothers
tailored
therapies.
These
offer
new
hope
patients
treatment-resistant
disorders,
highlighting
evolving
role
psychedelics
care.
ACS Medicinal Chemistry Letters,
Journal Year:
2024,
Volume and Issue:
15(12), P. 2080 - 2082
Published: Nov. 11, 2024
Psychedelic
compounds,
particularly
psilocybin
and
psilocin,
have
shown
significant
therapeutic
potential
in
treating
neurological
psychiatric
disorders.
However,
their
bioavailability,
rapid
metabolism,
stability
challenges
limited
clinical
use.
This
Patent
Highlight
reviews
recent
innovations
psychedelic
drug
delivery
systems
the
development
of
psilocin
analogs
aimed
at
improving
pharmacokinetic
pharmacodynamic
profiles.
Three
patents─focused
on
controlled-release
systems,
ester
analogs,
acetal/ketal
derivatives─present
novel
approaches
to
enhancing
stability,
efficacy
related
compounds.
These
advancements
promise
more
effective
treatments
for
conditions
such
as
depression,
chronic
pain,
neurodegenerative
diseases.
